HealthDay News — For individuals with type 2 diabetes, factors associated with weight gain after initiating insulin therapy include higher baseline glycated hemoglobin (A1c) and insulin dose requirements, and lower body mass index (BMI), according to a study published online May 13 in Diabetes Care.
Beverley Balkau, PhD, from the INSERM Centre for Research in Epidemiology and Population Health in Villejuif, France, and colleagues examined factors associated with weight gain one year after starting insulin treatment. Data were collected from 2,179 individuals with type 2 diabetes starting any insulin, from 314 centers in 12 countries.
The researchers found that the mean weight gain was 1.78 kg and almost one-quarter (24%) gained at least 5.0 kg. BMI, A1c, insulin regimen and dose, other glucose-lowering therapies, and hypertension were baseline factors associated with weight gain.
At one year, additional factors included A1c, insulin regimen and dose, and use of other glucose-lowering therapies. Weight gain at one year correlated with higher A1c at baseline, higher insulin dose at baseline and one year, and lower BMI at baseline, in multivariate analysis.
“By the time insulin was started, a high baseline A1c and insulin dose requirements were independently associated with greater weight gain, as was lower baseline BMI,” the researchers wrote. “Insulin regimen per se was not a predictive factor.”
Several authors disclosed financial ties to pharmaceutical companies, including Sanofi, which funded the study.